Canada's Milestone Pharma misses Q2 product revenue expectations
MIST•Outlook
- Milestone expects EMA decision on CARDAMYST for PSVT in H1 2027
- Company expects cash, equivalents and investments to fund operations into H2 2027
- Milestone plans to enroll first patient in AFib-RVR Phase 3 trial in H2 2026
Overview
- Canada biopharma's Q2 product revenue missed analyst expectations
- Net loss per share for Q2 widened to $0.21
- Company increased selling, general and administrative expenses due to CARDAMYST launch
Result Drivers
- Prescription growth - Co said CARDAMYST prescriptions and prescribers increased through Q2 following launch for PSVT
- Insurance coverage expansion - Co reported a significant recent increase in U.S. commercial insurance coverage for CARDAMYST
- Launch-related expenses - Co attributed higher selling, general and administrative expenses to personnel and operational costs related to CARDAMYST launch
Key details and analyst coverage
| Metric | Beat/Miss |
|---|
